Regulatory PathRegulatory requirements compared

Active substance

Flutamide

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
EULEXIN TAB 250MG250 mgTablet · Oral use100 BlisterSAR 472.50NCE · PrescriptionSCHERING-PLOUGHWithdrawn by MAH · Not Marketed
EULEXIN TAB 250MG250 mgTablet · Oral use20 BlisterSAR 109.65NCE · PrescriptionSCHERING-PLOUGHWithdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
FLUTAMIDE125MGcapsule · oralWAYLIS THERAPPrescription18 Sep 2001
EULEXIN125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**capsule · oralSCHERINGDiscontinued27 Jan 1989
FLUTAMIDE125MGcapsule · oralCHARTWELL RXDiscontinued18 Sep 2001
FLUTAMIDE125MGcapsule · oralACTAVIS LABS FL INCDiscontinued18 Sep 2001
FLUTAMIDE125MGcapsule · oralCIPLADiscontinued19 Sep 2001
FLUTAMIDE125MGcapsule · oralPHARMOBEDIENTDiscontinued9 May 2003

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
FLUTAMIDE02238560250 MGTABLET · ORALAA PHARMA INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffFlutamide 250mg tablets£167.8884 tablet1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

  • 8.2.4. Hormones and antihormones · complementary
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.